Tagrisso osimertinib regulatory update

The European Commission granted conditional approval of Tagrisso osimertinib from AstraZeneca to treat locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC). Tagrisso is an oral irreversible inhibitor of EGFR-activating mutations and the T790M EGFR resistance mutation. ...